(NASDAQ: PACB) Pacific Biosciences Of California's forecast annual revenue growth rate of 9.06% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Pacific Biosciences Of California's revenue in 2026 is $161,394,000.On average, 10 Wall Street analysts forecast PACB's revenue for 2026 to be $50,315,488,917, with the lowest PACB revenue forecast at $47,902,823,828, and the highest PACB revenue forecast at $52,243,117,574. On average, 10 Wall Street analysts forecast PACB's revenue for 2027 to be $57,284,367,194, with the lowest PACB revenue forecast at $51,520,256,827, and the highest PACB revenue forecast at $64,218,823,531.
In 2028, PACB is forecast to generate $65,742,776,706 in revenue, with the lowest revenue forecast at $60,811,051,441 and the highest revenue forecast at $71,572,601,686.